Maurie Markman, MD

Articles

Sometimes the Weight of Tradition Is Heavier Than Gold-Standard Evidence in Oncology

May 18th 2019

Evidence generated from the randomized study design may be largely ignored by an individual or a community of physicians if the results or strategies being examined do not align with existing beliefs or bias, local practice and referral patterns, and other potentially highly relevant factors unrelated to the trial outcome.

When the Quality of Evidence Just Doesn't Make the Grade in Cancer Care

May 10th 2019

The oncology clinical and research communities should demand that essential clinical trials and objectively valid evidence for efficacy and toxicity be obtained and reported before any regulatory agencies or national/international cancer societies support this strategy as a “standard of care” for cancer pain management.

Hope Versus Expectation: A Critical Distinction

April 26th 2019

It is critical to inquire what is wrong with hope, if it helps patients through their journey while not interfering with likely necessary end-of-life decisions when these are required to be made.

Old-Fashioned Biology Trumps Technological Potential

April 10th 2019

The recent technological advances in medicine and related fields have encouraged a belief among many that there is little technology will not be able to accomplish in improving cancer-related clinical outcomes, but it must be acknowledged that clinical medicine and cancer biology are extremely complex arenas.

Dose Modulation Should Not Be Undervalued in Oncology

March 28th 2019

Considering the decades of clinical investigation involving cytotoxic therapy of malignant disease, it is remarkable— even disconcerting—just how little is understood about the optimal delivery of this critical cancer treatment strategy.

When a Measure of Significance Is Not All That Significant

March 20th 2019

The term statistically significant is almost certainly beautiful music to the ears of clinical investigators and pharma/biotech companies. However, concern develops when one inquires how the most common test of significance, the P value, is used in clinical investigative efforts and whether at times this is more harmful than helpful within the domain of cancer medicine.

New Strategies and Novel Agents Transform Ovarian Cancer Into a Chronic Condition

March 7th 2019

The immediate future of clinical investigation in ovarian cancer is remarkably exciting, with a number of novel agents and combination strategies currently being examined in multiple clinical trials.

Germline Variants Assume Prominent Role in Oncology Treatment Paradigm

February 27th 2019

Stunning technological advances in the ability to examine the molecular structure of human DNA have significantly reduced the time and costs associated with this process.

Process Gets Overlooked in the Obsession With Outcomes in Oncology

February 14th 2019

It is essential to appreciate that precision cancer medicine is a process, not an event.

Intellectual Conflicts of Interest Pose Hidden Dangers to Scientific Accuracy

February 1st 2019

The model of an independent and self-regulating academic medical community continues to be challenged through widely reported accusations of serious scientific misconduct, failure of investigators to report potential financial conflicts of interest, and suggestions of inadequate transparency related to the questionable role of academic researchers in the analysis and reporting of industry-sponsored clinical trial results.

Dr. Markman Discusses Concept of Precision Medicine in Gynecologic Cancers

January 23rd 2019

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the concept of precision medicine in gynecologic cancers.

Be More Sensitive to the Toxicities of Cancer Therapy

January 16th 2019

The concept of chronic disease management in cancer has been and continues to be inadequately considered.

Dr. Markman on Cost Effectiveness of Precision Medicine in Gynecologic Cancers

January 15th 2019

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the cost effectiveness of precision medicine in gynecologic cancers.

Dr. Markman on Unmet Needs in Endometrial and Cervical Cancers

January 9th 2019

Dr. Markman Discusses Treating Ovarian Cancer as Chronic Disease

January 4th 2019

Added Factors Put the Overall Survival Endpoint to the Test

January 3rd 2019

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.

No Easy Answers for Discussing Outcomes With Patients

December 23rd 2018

Maurie Markman, MD, discusses how to address the important issue of survival following a cancer diagnosis.

Dr. Markman on Unmet Needs in Rare Gynecologic Cancers

December 12th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, 2018 Giant of Cancer Care for Gynecologic Cancers, discusses unmet needs in rare gynecologic cancers.

New Strategies Are Needed as Ovarian Cancer Becomes a Chronic Disease

December 10th 2018

Since the introduction of platinum agents in ovarian cancer, it is reasonable to suggest there have been only limited changes in the basic paradigm of ovarian cancer management over the past several decades.

A Strategy Built on Shared Values May Help Boost HPV Vaccination Rate

December 4th 2018

Maurie Markman, MD, discusses the steps that the scientific community needs to take to increase public acceptance of the vaccine against the human papillomavirus.